Once‐Daily Inhaled Budesonide for the Treatment of Asthma: Clinical Evidence and Pharmacokinetic Explanation

References

• Brattsand R, Selroos O. Current drugs for respiratory diseases. Drugs and the Lung, C P Page, W J Metzger. Raven Press, New York 1994; 101–220
   Google Scholar
• Lipworth B J. Airway and systemic effects of inhaled corticosteroids in asthma: dose response relationship. Pulm Pharmacol 1996; 9: 19–27
   PubMedGoogle Scholar
• Toogood J H, Baskerville J C, Jennings B, Lefcoe N M, Johansson S A. Influence of dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid, budesonide. J Allergy Clin Immunol 1982; 70: 288–298
   PubMed Web of Science ®Google Scholar
• Malo J‐L, Cartier A, Merland N, Ghezzo H, Burek A, Morris J, Jennings B H. Four‐times‐a‐day dosing frequency is better than a twice‐a‐day regimen in subjects requiring a high‐dose inhaled steroid, budesonide, to control moderate to severe asthma. Am Rev Respir Dis 1989; 140: 624–628
   PubMedGoogle Scholar
• McGivern D, Ward M, Macfarlane J, Roderick Smith W. Failure of once daily inhaled corticosteroid treatment to control chronic asthma. Thorax 1984; 39: 933–934
   PubMedGoogle Scholar
• Stiksa G, Glennow C. Once‐daily inhalation of budesonide in the treatment of chronic asthma: a clinical comparison. Ann Allergy 1985; 55: 49–51
   PubMedGoogle Scholar
• Mawhinney H, Spector S L, Kinsman R A, Siegel S C, Rachelefsky G S, Katz R M, Rohr A S. Compliance in clinical trials of two nonbronchodilator, antiasthma medications. Ann Allergy 1991; 66: 294–299
   PubMedGoogle Scholar
• Chmelik F, Doughty A. Objective measurements of compliance in asthma treatment. Ann Allergy 1994; 73: 527–532
   PubMedGoogle Scholar
• Thompson J, Irvine T, Grathwohl K, Roth B. Misuse of metered‐dose inhalers in hospitalized patients. Chest 1994; 105: 715–717
   PubMed Web of Science ®Google Scholar
• Cochrane M G, Bala M V, Downs K E, Mauskopf J, Ben‐Joseph R H. Inhaled corticosteroids for asthma therapy. Patient compliance, devices, and inhalation technique. Chest 2000; 117: 542–550
   PubMed Web of Science ®Google Scholar
• Hyland M E. Rationale for once‐daily therapy in asthma. Compliance issues. Drugs 1999; 58: 1–6
   PubMedGoogle Scholar
• Eisen S A, Miller D K, Woodward R S, Spitznagel E, Przybeck T R. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150: 1881–1884
   PubMed Web of Science ®Google Scholar
• Mann M, Eliasson O, Patel K, ZuWallack R L. A comparison of the effects of bid and qid dosing on compliance with inhaled flunisolide. Chest 1992; 101: 496–499
   PubMed Web of Science ®Google Scholar
• Bloom B S. Daily regimen and compliance with treatment. Fewer daily doses and drugs with fewer side effects improve compliance. BMJ 2001; 323: 647
   PubMed Web of Science ®Google Scholar
• Campbell L M, Watson D G, Venables T L, Taylor M D, Richardson P DI. Once daily budesonide Turbohaler compared with placebo as initial prophylactic therapy for asthma. Br J Clin Res 1991; 2: 111–122
   Google Scholar
• Jones A H, Langdon C G, Lee P S, Lingham S A, Nankani J P, Follows R MA, Tollemar U, Richardson P DI. Pulmicort® Turbohaler® once daily as initial prophylactic therapy for asthma. Respir Med 1994; 88: 293–299
   PubMed Web of Science ®Google Scholar
• Pauwels R A, Busse W W, O'Byrne P M, Pedersen S, Tan W C, Chen Y‐Z, Ohlsson S V, Ullman A. The inhaled steroid treatment as regular therapy in early asthma (START) study: rationale and design. Control Clin Trials 2001; 22: 405–419
   PubMedGoogle Scholar
• Pauwels R A, Pedersen S, Busse W W, Tan W C, Chen Y Z, Ohlsson S V, Ullman A, Lamm C J, O'Byrne P M. Early intervention with budesonide in mild persistent asthma: a randomised, double‐blind trial. Lancet 2003; 361: 1071–1076
   PubMed Web of Science ®Google Scholar
• Edsbäcker S, Brattsand R. Budesonide fatty‐acid esterification: a novel mechanism prolonging binding to airway tissue. Review of available data. Ann Allergy Asthma Immunol 2002; 88: 609–616
   PubMedGoogle Scholar
• Miller‐Larsson A, Mattsson H, Hjertberg E, Dahlbäck M, Tunek A, Brattsand R. Reversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos 1998; 26: 623–630
   PubMed Web of Science ®Google Scholar
• Tunek A, Sjödin K, Hallström G. Reversible formation of fatty acid esters of budesonide, an antiasthma glucocorticoid, in human lung and liver microsomes. Drug Metab Dispos 1997; 25: 1311–1317
   PubMed Web of Science ®Google Scholar
• Wieslander E, Delander E‐L, Sjödin K, Tunek A, Brattsand R. Fatty acid conjugation of budesonide in normal human bronchial epithelial cells. Am J Respir Crit Care Med 1998; 157: A402
   Google Scholar
• Wieslander E, Jerre A, Delander E‐L, Brattsand R. The prolonged activity of a budesonide pulse depends on its reversible intracellular esterification—studied in vitro. Am J Resp Crit Care Med 2000; 162(suppl. 3)A775
   PubMedGoogle Scholar
• Thorsson L, Thunnisen F BJM, Korn S, Carlshaf A, Edsbäcker S, Wouters E FM. Formation of fatty acid conjugates of budesonide in human lung tissue in vivo. Am J Respir Crit Care Med 1998; 157(Suppl. 3)A404
   Google Scholar
• Petersen H, Kullberg A, Edsbäcker S, Greiff L. Nasal retention of budesonide and fluticasone in man: formation of airway mucosal budesonide‐esters in vivo. Br J Clin Pharmacol 2001; 51: 159–163
   PubMed Web of Science ®Google Scholar
• Wieslander E I, Delander E L, Järkelid L, Hjertberg E, Tunek A, Brattsand R. Pharmacological importance of the reversible fatty acid conjugation of budesonide studied in a rat cell line in vitro. Am J Respir Cell Mol Biol 1998; 19: 477–484
   PubMed Web of Science ®Google Scholar
• Miller‐Larsson A, Jansson P, Runström A, Brattsand R. Prolonged airway activity and improved selectivity of budesonide possibly due to esterification. Am J Respir Crit Care Med 2000; 162: 1455–1461
   PubMed Web of Science ®Google Scholar
• Edsbäcker S, Jendbro M. Modes to achieve topical selectivity of inhaled glucocorticosteroids—focus on budesonide. Respir Drug Deliv 1998; VI: 71–82
   Google Scholar
• Jendbro M, Johansson C‐J, Strandberg P, Falk‐Nilsson H, Edsbäcker S. Pharmacokinetics of budesonide and its major ester metabolite after inhalation and intravenous administration of budesonide in the rat. Drug Metab Dispos 2001; 29: 769–776
   PubMed Web of Science ®Google Scholar
• Jendbro M, Johansson C‐J. Reversible glucocorticoid esterification. Inhaled Steroids in Asthma: Optimizing the Effects in the Airways, R P Schleimer, P M O'Bryne, S J Szefler, R Brattsand. Marcel Dekker, New York 2002; 309–330
   Google Scholar
• National Institutes of Health: National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program. Expert Panel Report II: Guidelines for the Diagnosis and Management of Asthma. National Institutes of Health, Bethesda, MD 1997, publication No. 97‐4051
   Google Scholar
• Banov C H, Howland W CI, Lumry W R. Once‐daily budesonide via Turbuhaler improves symptoms in adults with persistent asthma. Ann Allergy Asthma Immunol 2001; 86: 627–632
   PubMed Web of Science ®Google Scholar
• Raymundo A, Hampel F, Dukes E, Spino C. Budesonide 400 µg once daily via Turbuhaler® dry powder inhaler significantly improves asthma‐specific quality of Life (QOL) in adult patients with nonsteroid‐dependent asthma. Am J Respir Crit Care Med 1999; 159: A761
   Google Scholar
• Jónasson G, Carlsen K‐H, Blomqvist P. Clinical efficacy of low‐dose inhaled budesonide once or twice daily in children with mild asthma not previously treated with steroids. Eur Respir J 1998; 12: 1099–1104
   PubMedGoogle Scholar
• Jónasson G, Carlsen K‐H, Jonasson C, Mowinckel P. Low‐dose inhaled budesonide once or twice daily for 27 months in children with mild asthma. Allergy 2000; 55: 740–748
   PubMed Web of Science ®Google Scholar
• Herjavecz I, Blomqvist P, Serrano A. Efficacy of once‐ and twice‐daily administration of budesonide via Turbuhaler® as initial therapy in patients with mild persistent asthma. Respir Med 1999; 93: 230–235
   PubMed Web of Science ®Google Scholar
• van der Molen T, Meyboom‐de Jong B, Mulder H H, Postma D S. Starting with a higher dose of inhaled corticosteroids in primary care asthma treatment. Am J Respir Crit Care Med 1998; 158: 121–125
   PubMedGoogle Scholar
• Herrera‐Gatmaytan J J, Tuazon A O, Yangco R T. Comparison of once vs twice daily administration of inhaled budesonide in mild to moderate persistent asthma in children. Am J Respir Crit Care Med 2000; 161: A345
   PubMedGoogle Scholar
• McFadden E R, Casale T B, Edwards T B, Kemp J P, Metzger W J, Nelson H S, Storms W W, Neidl M J. Administration of budesonide once daily by means of Turbuhaler to subjects with stable asthma. J Allergy Clin Immunol 1999; 104: 46–52
   PubMed Web of Science ®Google Scholar
• Dukes E, Kemp J, Raymundo A. Budesonide 200 µg and 400 µg once daily via Turbuhaler® dry powder inhaler significantly improves asthma‐specific quality of life (QoL) in adult patients with stable asthma. J Allergy Clin Immunol 1999; 103(1 Part 2)S69
   Google Scholar
• Mintz S, Alexander M, Li J, Mayer P. Once‐daily administration of budesonide Turbuhaler® was as effective as twice‐daily treatment in patients with mild to moderate persistent asthma. J Asthma 2002; 39: 203–210
   PubMed Web of Science ®Google Scholar
• Metzger W. Efficacy and safety of once‐daily budesonide dry powder (Pulmicort Turbuhaler®) in adults with inhlaed steroid‐dependent asthma. J Allergy Clin Immunol 1999; 103(1, Part 2)S131
   Google Scholar
• Goldstein M, Banov C, Liljas B, Walton‐Bowen K, Hampel F. Once‐daily budesonide (Pulmicort Turbuhaler®) improves quality of life in adult asthmatics previously treated with inhaled corticosteroids. Ann Allergy Asthma Immunol 2000; 84: 161
   Google Scholar
• Shapiro G G, Mendelson L M, Pearlman D S. Once‐daily budesonide inhalation powder (Pulmicort Turbuhaler) maintains pulmonary function and symptoms of asthmatic children previously receiving inhaled corticosteroids. Ann Allergy Asthma Immunol 2001; 86: 633–640
   PubMedGoogle Scholar
• Campbell L M, Gooding T N, Aitchison W R, Smith N, Powell J A. Initial loading (400 µg twice daily) versus static (400 µg nocte) dose budesonide for asthma management. PLAN Research Group. Int J Clin Pract 1998; 52: 361–370
   PubMedGoogle Scholar
• Campbell L M, Gunn S D, Sweeney D, Smithers A J, Zurek A AA, Golightly L, Turbitt M L. Once daily budesonide: effective control of moderately severe asthma with 800 µg once daily inhaled via Turbohaler when compared with 400 µg twice daily. Eur J Clin Res 1995; 7: 1–14
   Google Scholar
• Schwarz D, Liebrich N, Huber R M. Vergleich der inhalativen Anvendung von Budesonid 800 µg einmal täglich gegenüber 2 × 400 µg bei Patienten mit leichtem bis mittel‐schweren Asthma bronchiale. Pneumologie 1997; 51: 171
   Google Scholar
• Vervloet D, Fontaine T, Bernabeu L, Gaillot P, Ostinelli J. Comparison of 800 µg once vs. 400 µg twice daily inhaled budesonide in patients with moderate asthma. Eur Respir J 2001; 18(suppl. 33)49S
   Google Scholar
• Chisholm S L, Dekker F W, Knuistingh Neven A, Petri H. Once‐daily budesonide in mild asthma. Respir Med 1998; 92: 421–425
   PubMedGoogle Scholar
• Buhl R, Creemers J PHM, Vondra V, Martelli N A. Once‐daily budesonide/formoterol via a single inhaler is effective in mild‐to‐moderate persistent asthma. Eur Respir J 2001; 18(suppl. 33)21S
   Google Scholar
• Kuna P, Chuchalin A, Ringdal N, De la Padilla E A, Black P, Lindqvist A, Nihlen U, Vogelmeier C. Low‐dose single‐inhaler budesonide/formonoterol administered once daily is effective in mild‐persistent asthma. Eur Respir J 2001; 33(suppl. 33)158S
   Google Scholar
• Möller C, Strömberg L, Oldaeus G, Arweström E, Kjellman M. Efficacy of once‐daily versus twice‐daily administration of budesonide by Turbuhaler® in children with stable asthma. Pediatr Pulmonol 1999; 28: 337–343
   PubMed Web of Science ®Google Scholar
• Campbell L M, Bodalia B, Gogbashian C A, Gunn S D, Humphreys P J, Powell J P. Once‐daily budesonide: 400 µg once daily is as effective as 200 µg twice daily in controlling childhood asthma. Int J Clin Pract 1998; 52: 213–219
   PubMed Web of Science ®Google Scholar
• Venables T L, Addlestone M B, Smithers A J, Blagden M D, Weston D, Gooding T, Carr E P, Follows R MA. A comparison of the efficacy and patient acceptability of once daily budesonide via Turbohaler and twice daily fluticasone propionate via disc‐inhaler at an equal daily dose of 400 µg in adult asthmatics. Br J Clin Res 1996; 7: 15–32
   Google Scholar
• Gunn S D, Choudhury M, Au K, Burnett R J, Black H L, Turbitt M L. Inhaled steroid treatment reduction in stable asthmatics: a comparison of beclomethasone/budesonide metered dose inhaler with half dose treatment using budesonide Turbohaler®, given once or twice daily. Br J Clin Res 1997; 8: 67–80
   Google Scholar
• Kemp J P, Skoner D P, Szefler S J, Walton‐Bowen K, Cruz‐Rivera M, Smith J A. Once‐daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children. Ann Allergy Asthma Immunol 1999; 83: 231–239
   PubMed Web of Science ®Google Scholar
• Baker J W, Mellon M, Wald J, Welch M, Cruz‐Rivera M, Walton‐Bowen K. A multiple‐dosing, placebo‐controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants. Paediatrics 1999; 103: 414–421
   PubMed Web of Science ®Google Scholar
• Scott M, Ellis M, Cruz‐Rivera M, Walton‐Bowen K, Smith J. Improved asthma control with once‐daily budesonide inhalation suspension (BIS; Pulmicort Respules™) in children < 4 and > 4 years of age. J Allergy Clin Immunol 1999; 103(1 Part 2)S130
   Google Scholar
• Mellon M. Efficacy of budesonide inhalation suspension in infants and young children with persistent asthma. J Allergy Clin Immunol 1999; 104(No. 4 Part 2)S191–S199
   PubMedGoogle Scholar
• Szefler S, Eigen H. Budesonide inhalation suspension: a nebulized corticosteroid persistent asthma. J Allergy Clin Immunol 2002; 109: 730–742
   PubMed Web of Science ®Google Scholar
• Leflein J G, Szefler S J, Murphy K R, Fitzpatrick S, Cruz‐Rivera M, Miller C J, Smith J A. Nebulized budesonide inhalation suspension compared with cromolyn sodium nebulizer solution for asthma in young children: results of a randomized outcomes trial. Pediatrics 2002; 109: 866–872
   PubMed Web of Science ®Google Scholar
• Selroos O, Backman R, Forsén K‐O, Löfroos A‐B, Niemistö M, Pietinalho A, Äikäs C, Riska H. Local side‐effects during 4‐year treatment with inhaled corticosteroids—a comparison between pressurized metered‐dose inhalers and Turbuhaler®. Allergy 1994; 49: 888–890
   PubMedGoogle Scholar
• Andersson N, Källen A, Thorsson L. A randomized controlled assessment of the effects of different dosing regimens of budesonide on the HPA‐axis in healthy subjects. Br J Clin Pharmacol 2001; 51: 325–328
   PubMedGoogle Scholar
• Thorsson L, Källen A. A randomized controlled assessment of the systemic activity of budesonide when given once or twice daily via Turbuhaler. Eur J Clin Pharmacol 2000; 56: 207–210
   PubMedGoogle Scholar
• Wilson A M, Clark D J, Devlin M M, McFarlane L C, Lipworth B J. Adrenocortical activity with repeated administration of one‐daily inhaled fluticasone propionate and budesonide in asthmatic adults. Eur J Clin Pharmacol 1998; 53: 317–320
   PubMedGoogle Scholar
• Irani A‐M, Cruz‐Rivera M, Fitzpatrick S, Hoag J, Smith J. Effects of budesonide inhalation suspension on hypothalamic‐pituitary‐adrenal‐axis function in infants and young children with persistent asthma. Ann Allergy Asthma Immunol 2002; 88: 306–312
   PubMedGoogle Scholar
• Scott M B, Skoner D P. Short‐term and long‐term safety of budesonide inhalation suspension in infants and young children with persistent asthma. J Allergy Clin Immunol 1999; 104(4 part 2)S200–S209
   PubMedGoogle Scholar
• Heuck C, Wolthers O D, Kollerup G, Hansen M, Teisner B. Adverse effects of inhaled budesonide (800 µg) on growth and collagen turnover in children with asthma: a double‐blind comparison of once‐daily versus twice‐daily administration. J Pediatr 1998; 133: 608–612
   PubMed Web of Science ®Google Scholar
• Barnes P J, Pedersen S, Busse W W. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998; 157(No. 3 pt. 2 Suppl)S1–S53
   PubMedGoogle Scholar
• Agertoft L, Pedersen S. Effect of long‐term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 2000; 343: 1064–1069
   PubMed Web of Science ®Google Scholar
• Noonan M, Karpel J, Bensch G, Ramsdell J, Webb D, Nolop K. Comparison of once‐daily to twice‐daily treatment with mometasone furoate dry powder inhaler. Ann Allergy Asthma Immunol 2001; 86: 36–43
   PubMed Web of Science ®Google Scholar
• Edsbäcker S. Uptake, retention, and biotransformation of corticosteroids in the lung and airways. Inhaled Steroids in Asthma: Optimizing Effects in the Airways, R P Schleimer, P M O'Byrne, S J Szefler, R Brattsand. Marcel Dekker, New York 2002; 213–246
   Google Scholar
• Munch E P, Laursen L C, Dirksen A, Weeke E R, Weeke B. Dose frequency in the treatment of asthmatics with inhaled topical steroids. Comparison between a twice daily and a once daily dosing regimen. Eur J Respir Dis 1985; 67: 254–260
   PubMedGoogle Scholar
• Gagnon M, Côte J, Milot J, Turcotte H, Boulet L‐P. Comparative safety and efficacy of single or twice daily administration of inhaled beclomethasone in moderate asthma. Chest 1994; 105: 1732–1737
   PubMedGoogle Scholar
• ZuWallack R L, Rosen J P, Cohen L, et al. The effectiveness of once‐daily dosing of inhaled flunisolide in maintaining asthma control. J Allergy Clin Immunol 1997; 99: 278–285
   PubMed Web of Science ®Google Scholar
• Pincus D J, Szefler S J, Ackerson L M, Martin R J. Chronotherapy of asthma with inhaled steroids: the effect of dosage timing on drug eficacy. J Allergy Clin Immunol 1995; 95: 1172–1178
   PubMed Web of Science ®Google Scholar
• Pincus D J, Humeston T R, Martin R J. Further studies on the chronotherapy of asthma with inhaled steroids: the effect of dosage timing on drug efficacy. J Allergy Clin Immunol 1997; 100: 771–774
   PubMed Web of Science ®Google Scholar
• Martin R J, Cicutto L C, Smith H R, Ballard R D, Szefler S J. Aiway inflammation in nocturnal asthma. Am Rev Respir Dis 1991; 143: 351–357
   PubMed Web of Science ®Google Scholar
• Postma D S, Sevette C, Martinat Y, Schlösser N, Aumann J, Kafé H. Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur Respir J 2001; 17: 1083–1088
   PubMed Web of Science ®Google Scholar
• Nathan R A, Li J TC, Finn A, Jones R, Payne J E, Wolford J P, Harding S M. A dose‐ranging study of fluticasone propionate administered once daily via multidose powder inhaler to patients with moderate asthma. Chest 2000; 118: 296–302
   PubMedGoogle Scholar
• Wolfe J, Rooklin A, Grady J, Munk Z M, Stevens A, Prillaman B, Duke S, Harding S. Comparison of once‐and twice‐daily dosing of fluticasone propionate 200 micrograms per day administered by Diskus device in patients with asthma treated with or without inhaled corticosteroids. J Allergy Clin Immunol 2000; 105: 1153–1161
   PubMedGoogle Scholar
• ZuWallack R, Adelglass J, Clifford D P, Duke S P, Wire P D, Faris M, Harding S M. Long‐term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma. Chest 2000; 118: 303–312
   PubMed Web of Science ®Google Scholar
• Boulet L P, Cowie R L, Dal Negro R, Brett W, Gold M, Marques A, Thorburn W S, Stepner N M, Robson R. Comparison of once‐with twice‐daily dosing of fluticasone propionate in mild and moderate asthma. Can Respir J 2000; 7: 239–247
   PubMedGoogle Scholar
• Purucker M E, Rosenbraugh C J, Zhou F, Meyer R J. Inhaled fluticasone propionate by Diskus in the treatment of asthma. A comparison of the efficacy of the same nominal dose given either once or twice a day. Chest 2003; 124: 1584–1593
   PubMed Web of Science ®Google Scholar
• Kemp J P, Berkowitz R B, Miller S D, Murray J J, Nolop K, Harrison J E. Mometasone furoate administered once daily is as effective as twice‐daily administration for treatment of mild‐to‐moderate persistent asthma. J Allergy Clin Immunol 2000; 106: 485–492
   PubMed Web of Science ®Google Scholar
• Parameswaran K, O'Byrne P M, Sears M R. Inhaled corticosteroids for asthma: common clinical quandaries. J Asthma 2003; 40: 107–118
   PubMed Web of Science ®Google Scholar
• Boulet L‐P. Once‐daily inhaled corticosteroids for the treatment of asthma. Curr Opin Pulm Med 2003; 10: 15–21
   Google Scholar